Hedge Fund Elliott Management has bought a big stake in BioMarin Pharma, causing a spike in the company’s share price, and started discussions with the company about its s
Activist hedge fund Bluebell Capital Partners has joined Elliott Investment in taking a stake in GlaxoSmithKline and pushing for change at the pharma company.
GlaxoSmithKline's board had responded to the broadside attack delivered by activist investor Elliott Management yesterday, saying it stands firmly behind the leadership of chief executive E
GlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm's prospects at an investor meeting last week would deflect criticism of her leadershi
GlaxoSmithKline has sold its entire stake in its respiratory partner Innoviva, raising $392 million and simplifying its business ahead of a split into two.
Speculation is mounting GlaxoSmithKline's CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the dreaded activist investor Elliott Management built a stake
An oral therapy that can allow children and adolescents with an aggressive form of brain cancer to be treated at home rather than in hospital has been recommended for use
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.